Oruka Therapeutics, Inc. (ORKA)
US — Healthcare Sector
Peers:
Automate Your Wheel Strategy on ORKA
With Tiblio's Option Bot, you can configure your own wheel strategy including ORKA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ORKA
- Rev/Share 0.0
- Book/Share 8.7507
- PB 1.6216
- Debt/Equity 0.0026
- CurrentRatio 30.0335
- ROIC -0.232
- MktCap 531280695.0
- FreeCF/Share -1.7933
- PFCF -7.1078
- PE -7.8436
- Debt/Assets 0.0025
- DivYield 1.3641
- ROE -0.2688
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Initiation | ORKA | BTIG Research | -- | Buy | -- | $44 | May 22, 2025 |
Initiation | ORKA | Wolfe Research | -- | Outperform | -- | $20 | Feb. 4, 2025 |
Initiation | ORKA | Stifel | -- | Buy | -- | $49 | Oct. 11, 2024 |
Initiation | ORKA | H.C. Wainwright | -- | Buy | -- | $45 | Oct. 7, 2024 |
Initiation | ORKA | Leerink Partners | -- | Outperform | -- | $44 | Sept. 17, 2024 |
Initiation | ORKA | TD Cowen | -- | Buy | -- | -- | Sept. 16, 2024 |
Initiation | ORKA | Jefferies | -- | Buy | -- | $40 | Sept. 13, 2024 |
News
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
ORKA
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026
Read More
Oruka Therapeutics to Present at Multiple March Investor Conferences
ORKA
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:
Read More
About Oruka Therapeutics, Inc. (ORKA)
- IPO Date
- Website http://www.orukatx.com
- Industry Biotechnology
- CEO Lawrence Otto Klein
- Employees 28
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.